Deferred Tax Assets, Valuation Allowance of GYRE THERAPEUTICS, INC. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
GYRE THERAPEUTICS, INC. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • GYRE THERAPEUTICS, INC. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $70,148,000, a 6.9% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

GYRE THERAPEUTICS, INC. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $70,148,000 +$4,543,000 +6.9% 31 Dec 2025 10-K 13 Mar 2026 2025 FY
Q4 2024 $65,605,000 +$1,832,000 +2.9% 31 Dec 2024 10-K 13 Mar 2026 2025 FY
Q4 2023 $63,773,000 +$7,757,000 +14% 31 Dec 2023 10-K 13 Mar 2026 2025 FY
Q4 2022 $56,016,000 -$5,467,000 -8.9% 31 Dec 2022 10-K 30 Mar 2023 2022 FY
Q4 2021 $61,483,000 +$23,087,000 +60% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q4 2020 $38,396,000 -$6,887,000 -15% 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q4 2019 $45,283,000 +$17,198,000 +61% 31 Dec 2019 10-K 04 Mar 2021 2020 FY
Q4 2018 $28,085,000 +$11,820,000 +73% 31 Dec 2018 10-K 20 Feb 2020 2019 FY
Q4 2017 $16,265,000 -$14,104,000 -46% 31 Dec 2017 10-K 08 Mar 2019 2018 FY
Q4 2016 $30,369,000 +$8,714,000 +40% 31 Dec 2016 10-K 19 Mar 2018 2017 FY
Q4 2015 $21,655,000 -$30,320,000 -58% 31 Dec 2015 10-K 08 Mar 2017 2016 FY
Q4 2014 $51,975,000 +$2,106,000 +4.2% 31 Dec 2014 10-K 09 Mar 2016 2015 FY
Q4 2013 $49,869,000 -$34,232,000 -41% 31 Dec 2013 8-K/A 23 Oct 2015
Q4 2012 $84,101,000 +$1,745,000 +2.1% 31 Dec 2012 10-K 14 Mar 2014 2013 FY
Q4 2011 $82,356,000 31 Dec 2011 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.